MHRA approves melatonin solution for children and adolescents with ADHD

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Colonis’ Melatonin 1mg/ml Oral Solution as a treatment to improve sleep in children and adolescents with attention-deficit hyperactivity disorder (ADHD), the manufacturer has announced.

Insomnia
Children with ADHD are more likely to suffer from sleep onset insomnia

The prescription-only medicine is suitable for those aged 6-17 for whom other sleep hygiene measures have been inadequate, Colonis said in a release yesterday (October 3).

The recommended dose starts from 1-2 mg, to be taken 30-60 minutes before bedtime.

Children with ADHD are more likely to suffer from sleep onset insomnia, which is characterised by difficulty in falling asleep, the manufacturer said.

Colonis director of medical affairs Henno Welgemoed welcomed the MHRA’s approval.

“This approval provides a valuable treatment option for children and adolescents suffering with ADHD and sleep onset insomnia,” he said.

Pharmacists can order Colonis’ Melatonin 1mg/ml Oral Solution from all the mainline wholesalers.

The product is listed in October’s drug tariff at £155.57 for a 150ml bottle.

Sign in or register for free

Latest from News

Patient secures ‘urgent’ leukaemia treatment after Pharmacy First consultation

 
• By 
 • comment

A pharmacist has been hailed as “incredible” after she spotted a patient’s leukaemia red flags during an NHS Pharmacy First Plus consultation.

PDA releases ‘six-step test’ for the next funding contract

 
• By 
 • comment

It assesses whether the next funding contract will support pharmacists, keep patients safe, and offer long-term sustainability.

Assisted dying: Pharmacists’ voices are ‘missing’ from dialogue

 
• By 
 • comment

Experts have long been calling for pharmacists to be able to conscientiously object to taking part in the assisted dying process, but one researcher argues that pharmacists’ voices are “missing” from this dialogue.

More from Clinical